Balaji Tamarappoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Balaji Tamarappoo has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Daniel S. Berman
Cedars-Sinai Medical Center, Los Angeles, CA (D.S.B.).
6 shared publications - Damini Dey
Cedars-Sinai Medical Center, Los Angeles, CA, United States
5 shared publications Heidi Gransar
Department of Imaging, Mark Taper Imaging Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
3 shared publications- Heidi Gransar
Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
3 shared publications Louise Thomson
Department of Imaging, Mark Taper Imaging Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
3 shared publications- Piotr J. Slomka
Artificial Intelligence in Medicine Research Center, Departments of Biomedical Sciences, Medicine, and Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, United States
3 shared publications
Latest Publications
- 1 December 2021
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 14 (12) , 2337-2349
Diagnostic Accuracy of Cardiovascular Magnetic Resonance for Cardiac Transplant Rejection
- 1 December 2021
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 14 (12) , 2337-2349
Diagnostic Accuracy of Cardiovascular Magnetic Resonance for Cardiac Transplant Rejection
- Open Access
- 29 September 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (10) , 3143
The Impact of Valvuloarterial Impedance on Left Ventricular Geometrical Change after Transcatheter Aortic Valve Replacement: A Comparison between Valvuloarterial Impedance and Mean Pressure Gradient
Increase in left ventricular (LV) mass develops as a compensatory mechanism against pressure overload in aortic valve stenosis. However, long-standing LV geometrical changes are related to poor prognosis. The LV geometrical change occurs after transcatheter aortic valve replacement (TAVR). The present study aimed to investigate the relationship between improvement in valvuloarterial impedance (Zva) and change in LV mass index (LVMI) and the ratio of LVMI to LV end-diastolic volume index (LVMI/LVEDVI). We compared these relationships to that between Zva and mean pressure gradient (MPG). Baseline and follow-up transthoracic echocardiograms of 301 patients who underwent TAVR from November 2011 to December 2015 were reviewed. Spearman correlation coefficient (ρ) was used to compare ΔLVMI and ΔLVMI/LVEDVI with Zva or MPG. The correlation between ΔZva and ΔLVMI (ρ = 0.47, p < 0.001) was superior to that between ΔMPG and ΔLVMI (ρ = 0.15, p = 0.009) (p for comparison < 0.001). The correlation between ΔZva and ΔLVMI/LVEDVI was statistically significant (ρ = 0.54, p < 0.001); in contrast, that of ΔMPG and ΔLVMI/LVEDVI was not. The improvement in Zva after TAVR was more closely related to LVMI and LVMI/LVEDVI reduction than MPG reduction.
- 29 September 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (10) , 3143
Open AccessThe Impact of Valvuloarterial Impedance on Left Ventricular Geometrical Change after Transcatheter Aortic Valve Replacement: A Comparison between Valvuloarterial Impedance and Mean Pressure Gradient
Increase in left ventricular (LV) mass develops as a compensatory mechanism against pressure overload in aortic valve stenosis. However, long-standing LV geometrical changes are related to poor prognosis. The LV geometrical change occurs after transcatheter aortic valve replacement (TAVR). The present study aimed to investigate the relationship between improvement in valvuloarterial impedance (Zva) and change in LV mass index (LVMI) and the ratio of LVMI to LV end-diastolic volume index (LVMI/LVEDVI). We compared these relationships to that between Zva and mean pressure gradient (MPG). Baseline and follow-up transthoracic echocardiograms of 301 patients who underwent TAVR from November 2011 to December 2015 were reviewed. Spearman correlation coefficient (ρ) was used to compare ΔLVMI and ΔLVMI/LVEDVI with Zva or MPG. The correlation between ΔZva and ΔLVMI (ρ = 0.47, p < 0.001) was superior to that between ΔMPG and ΔLVMI (ρ = 0.15, p = 0.009) (p for comparison < 0.001). The correlation between ΔZva and ΔLVMI/LVEDVI was statistically significant (ρ = 0.54, p < 0.001); in contrast, that of ΔMPG and ΔLVMI/LVEDVI was not. The improvement in Zva after TAVR was more closely related to LVMI and LVMI/LVEDVI reduction than MPG reduction.
- 29 August 2019
- Published by Wiley in Clinical Transplantation
- Vol. 33 (10) , e13704
Quantitative myocardial tissue characterization by cardiac magnetic resonance in heart transplant patients with suspected cardiac rejection
Distinct histopathologic changes occur in acute cellular rejection (ACR), antibody‐mediated rejection (AMR), and biopsy‐negative rejection (BNR). Cardiovascular magnetic resonance (CMR)‐based myocardial tissue characterization can be used to quantify these changes. We assessed T1, T2, and extracellular volume fraction (ECV) by CMR in patients with subtypes of rejection. T1, T2, and ECV were quantified at the mid‐ventricular level and compared between patients with and without rejection. The association between quantitative tissue characteristics and the combined outcome of death, retransplantation, heart failure hospitalization, or myocardial infarction was evaluated with a Cox‐proportional hazards model. In 46 patients, mean age 53.3 ± 13.7 years, 71.7% male, at a median of 7.4 years from transplant, average myocardial T1 was increased in BNR compared with no rejection (1057 vs 1012 msec, P = .006). Average myocardial T2 was elevated in all types of rejection, P < .05. In a cox‐proportional hazards model, higher T2 values were associated with an increase in the combined clinical outcome (adjusted HR 1.21, 95% CI 1.06‐1.37, P = .004) after adjusting for left ventricular mass index. Myocardial tissue characteristics are abnormal in all subtypes of rejection, and abnormal T2 quantified by CMR provides additional prognostic value.
- 29 August 2019
- Published by Wiley in Clinical Transplantation
- Vol. 33 (10) , e13704
Quantitative myocardial tissue characterization by cardiac magnetic resonance in heart transplant patients with suspected cardiac rejection
Distinct histopathologic changes occur in acute cellular rejection (ACR), antibody‐mediated rejection (AMR), and biopsy‐negative rejection (BNR). Cardiovascular magnetic resonance (CMR)‐based myocardial tissue characterization can be used to quantify these changes. We assessed T1, T2, and extracellular volume fraction (ECV) by CMR in patients with subtypes of rejection. T1, T2, and ECV were quantified at the mid‐ventricular level and compared between patients with and without rejection. The association between quantitative tissue characteristics and the combined outcome of death, retransplantation, heart failure hospitalization, or myocardial infarction was evaluated with a Cox‐proportional hazards model. In 46 patients, mean age 53.3 ± 13.7 years, 71.7% male, at a median of 7.4 years from transplant, average myocardial T1 was increased in BNR compared with no rejection (1057 vs 1012 msec, P = .006). Average myocardial T2 was elevated in all types of rejection, P < .05. In a cox‐proportional hazards model, higher T2 values were associated with an increase in the combined clinical outcome (adjusted HR 1.21, 95% CI 1.06‐1.37, P = .004) after adjusting for left ventricular mass index. Myocardial tissue characteristics are abnormal in all subtypes of rejection, and abnormal T2 quantified by CMR provides additional prognostic value.
- Open Access
- 6 May 2019
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 13 (1) , 1-6
Progression of coronary microvascular dysfunction to heart failure with preserved ejection fraction: a case report
In women with evidence of ischemia and no obstructive coronary artery disease the underlying mechanism is most often attributed to coronary microvascular dysfunction. Higher rates of adverse cardiovascular events, specifically heart failure with preserved ejection fraction, are present in women with coronary microvascular dysfunction, leading to the hypothesis that coronary microvascular dysfunction may contribute to the progression of heart failure with preserved ejection fraction. A 55-year-old, Caucasian woman with a past medical history of chest pain and shortness of breath was referred to our tertiary care center and diagnosed as having coronary microvascular dysfunction by invasive coronary reactivity testing. After 10 years of follow-up care for coronary microvascular dysfunction, she presented to an emergency room in acute heart failure and was diagnosed as having heart failure with preserved ejection fraction. The current case report provides a specific example in support of existing studies that demonstrate that coronary microvascular dysfunction may be a precursor of heart failure with preserved ejection fraction. Further research is needed to establish causality and management. Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT02582021 .
- 6 May 2019
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 13 (1) , 1-6
Open AccessProgression of coronary microvascular dysfunction to heart failure with preserved ejection fraction: a case report
In women with evidence of ischemia and no obstructive coronary artery disease the underlying mechanism is most often attributed to coronary microvascular dysfunction. Higher rates of adverse cardiovascular events, specifically heart failure with preserved ejection fraction, are present in women with coronary microvascular dysfunction, leading to the hypothesis that coronary microvascular dysfunction may contribute to the progression of heart failure with preserved ejection fraction. A 55-year-old, Caucasian woman with a past medical history of chest pain and shortness of breath was referred to our tertiary care center and diagnosed as having coronary microvascular dysfunction by invasive coronary reactivity testing. After 10 years of follow-up care for coronary microvascular dysfunction, she presented to an emergency room in acute heart failure and was diagnosed as having heart failure with preserved ejection fraction. The current case report provides a specific example in support of existing studies that demonstrate that coronary microvascular dysfunction may be a precursor of heart failure with preserved ejection fraction. Further research is needed to establish causality and management. Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT02582021 .
- 1 September 2018
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 12 (5) , 385-390
Improvement in LDL is associated with decrease in non-calcified plaque volume on coronary CTA as measured by automated quantitative software
- 1 September 2018
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 12 (5) , 385-390
Improvement in LDL is associated with decrease in non-calcified plaque volume on coronary CTA as measured by automated quantitative software
- 1 September 2018
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 12 (5) , 379-384
Non-invasive fractional flow reserve in vessels without severe obstructive stenosis is associated with coronary plaque burden
- 1 September 2018
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 12 (5) , 379-384
Non-invasive fractional flow reserve in vessels without severe obstructive stenosis is associated with coronary plaque burden
- 1 July 2018
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 11 (7) , 1000-1009
Prognostic Value of Combined Clinical and Myocardial Perfusion Imaging Data Using Machine Learning
- 1 July 2018
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 11 (7) , 1000-1009
Prognostic Value of Combined Clinical and Myocardial Perfusion Imaging Data Using Machine Learning
- Top Cited Papers
- 1 January 2018
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 12 (1) , 67-73
Epicardial adipose tissue density and volume are related to subclinical atherosclerosis, inflammation and major adverse cardiac events in asymptomatic subjects
- 1 January 2018
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 12 (1) , 67-73
Top Cited PapersEpicardial adipose tissue density and volume are related to subclinical atherosclerosis, inflammation and major adverse cardiac events in asymptomatic subjects
- 1 May 2017
- Published by Elsevier in The American Journal of Cardiology
- Vol. 119 (10) , 1663-1669
Incremental Prognostic Value of Global Longitudinal Strain and 18F-Fludeoxyglucose Positron Emission Tomography in Patients With Systemic Sarcoidosis
- 1 May 2017
- Published by Elsevier in The American Journal of Cardiology
- Vol. 119 (10) , 1663-1669
Incremental Prognostic Value of Global Longitudinal Strain and 18F-Fludeoxyglucose Positron Emission Tomography in Patients With Systemic Sarcoidosis
- Open Access
- 9 February 2017
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 58 (3) , 359-364
Molecular Imaging of Vulnerable Coronary Plaque: A Pathophysiologic Perspective
Atherothrombotic events in coronary arteries are most often due to rupture of unstable plaque resulting in myocardial infarction. Radiolabeled molecular imaging tracers directed toward cellular targets that are unique to unstable plaque can serve as a powerful tool for identifying high-risk patients and for assessing the potential of new therapeutic approaches. Two commonly available radiopharmaceuticals—18F-FDG and 18F-NaF—have been used in clinical research for imaging coronary artery plaque, and ongoing clinical studies are testing whether there is an association between 18F-NaF uptake and future atherothrombotic events. Other, less available, tracers that target macrophages, endothelial cells, and apoptotic cells have also been tested in small groups of patients. Adoption of molecular imaging of coronary plaque into clinical practice will depend on overcoming major hurdles, ultimately including evidence that the detection of unstable plaque can change patient management and improve outcomes.
- 9 February 2017
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 58 (3) , 359-364
Open AccessMolecular Imaging of Vulnerable Coronary Plaque: A Pathophysiologic Perspective
Atherothrombotic events in coronary arteries are most often due to rupture of unstable plaque resulting in myocardial infarction. Radiolabeled molecular imaging tracers directed toward cellular targets that are unique to unstable plaque can serve as a powerful tool for identifying high-risk patients and for assessing the potential of new therapeutic approaches. Two commonly available radiopharmaceuticals—18F-FDG and 18F-NaF—have been used in clinical research for imaging coronary artery plaque, and ongoing clinical studies are testing whether there is an association between 18F-NaF uptake and future atherothrombotic events. Other, less available, tracers that target macrophages, endothelial cells, and apoptotic cells have also been tested in small groups of patients. Adoption of molecular imaging of coronary plaque into clinical practice will depend on overcoming major hurdles, ultimately including evidence that the detection of unstable plaque can change patient management and improve outcomes.